ReviewCancer management and research2019
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Jan Philipp Bewersdorf et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this paperpooled ittrialcites it